Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

13 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) Immunoblots of MPM cells treated with the indicated concentrations of crizotinib alone for 24 h with HGF stimulation.

    Sci Rep, 2016, 6:32992. Crizotinib (PF-02341066) purchased from Selleck.

  • Three MET amplified (Hs746t, SNU-5 and MKN45) and two non-amplified cell lines (MKN74 and NUGC-4) were incubated with or without 100nM crizotinib 24 hours, and total protein was extracted using RIPA lysis buffer. Total lysates were then analyzed by immunoblotting using anti-phospho-MET, anti-total-MET, and β-actin antibodies.

    Oncotarget, 2017, 8(31):51675-51687. Crizotinib (PF-02341066) purchased from Selleck.

    Viability of Ba/F3 cells stably expressing DCTN1-ALK or EML4-ALK cDNAs after treatment with crizotinib (C). Ba/F3 cells transduced with lentiviral cDNA or empty vector were subjected to the assay, and the number of cells was counted at 72 hours.

    Oncologist, 2017, 22(2):158-164. Crizotinib (PF-02341066) purchased from Selleck.

  • Combination of EGCG with c-MET inhibitor has enhanced inhibitory effects on the growth of OS cells. MG-63 and U-2OS cells were treated with crizotinib (0.05 mM) and/or EGCG (0.08 g/L) for 48 h, and the effects on cell apoptosis (b) were determined using flow cytometry. *P<0.05 versus the control; #P<0.05 versus crizotinib-treated groups or EGCG-treated groups

    Tumour Biol, 2016, 37(4):4373-82. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Crizotinib impaired tumor vascularization. a-e Representative photomicrographs (40×) of CD31 staining in negative control and indicated LFD, HFD, vehicle (veh) and crizotinib (criz) treated groups. b CD31 was quantified on 5–6 randomly selected regions of n = 2 sections each from each mouse. N = 9–10 mice (a vs b, Veh vs Criz, P = 0.0138)

    Springerplus, 2016, 5:348. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NHzxOpNEgXSxdH;4bYMhSXO|YYm= MXK0PEBp MYPEUXNQ Mn;RR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= NX3Te4lVOjF3N{K1PFk>
BAF3 NHjafY9EgXSxdH;4bYMhSXO|YYm= M33Ie|Q5KGh? NEDG[5pFVVOR MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochSUyNIFyxNVk3VSCvdYThcpQh[2:neIDy[ZN{cW6pIFXNUFQhf2m2aDDJR|UxKG:oIEKuNkDPxE1? NX7FcXoxOjF3N{K1PFk>
BAF3 NUfZXZNNS3m2b4TvfIlkKEG|c3H5 M2rnelQ5KGh? M4Phc2ROW09? M1uyd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2= M3PhS|IyPTd{NUi5
Kelly M1\K[2N6fG:2b4jpZ{BCe3OjeR?= NXTCephsTE2VTx?= MlXJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4VtdHliY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCC5aYToJGlEPTBib3[gNE41OiEQvF2= NI\UVWozOTV5MkW4PS=>
SH-SY5Y NVG5TFVES3m2b4TvfIlkKEG|c3H5 NEjaXYpFVVOR MnK4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjV|IN88US=> NFTBNmkzOTV5MkW4PS=>
SMS-KCN M{D6PWN6fG:2b4jpZ{BCe3OjeR?= MnXLSG1UVw>? M{THPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNOWy2NQ16gZ4VtdHNiZYjwdoV{e2mwZzDBUGshWjF{N{XRJI12fGGwdDD3bZRpKEmFNUCgc4YhOC57MTFOwG0> M3nIWFIyPTd{NUi5
BAF3 NXHEZYNOS3m2b4TvfIlkKEG|c3H5 MWS0PEBp M3y4R2ROW09? M1PCWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCWZXytRWxMKHerdHigTWM2OCCxZjCwMlE6KM7:TR?= MUWyNVU4OjV6OR?=
3T3 M1zrSGZ2dmO2aX;uJGF{e2G7 NGrYV5QyKGh? MXnEUXNQ M4\DVGlvcGmkaYTpc44hd2ZiUl;OJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? MYWyNVgyOjRzNB?=
3T3-E NIPwTm5HfW6ldHnvckBCe3OjeR?= NIm5bYUyKGh? NGPBclFFVVOR NXHLUWp2UW6qaXLpeIlwdiCxZjDUTWUzKGG|c3Xzd4VlKGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkS0PEDPxE1? NFvucokzOThzMkSxOC=>
A549 NHLFe2JMcW6jc3WgRZN{[Xl? NVz4fm1FOSCq NVP0SnVOTE2VTx?= M2Pmc2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=> M4SzS|IyQDF{NEG0
BAF3-BCL M2PvZ2Z2dmO2aX;uJGF{e2G7 Mni5NUBp MYDEUXNQ NHTjU3NKdmirYnn0bY9vKG:oIFHCUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMT6xOVkh|ryP NFTGengzOThzMkSxOC=>
HEK293 MmjwSpVv[3Srb36gRZN{[Xl? NGPFNW0yKGh? NYrhbIhpTE2VTx?= M1nafWlvcGmkaYTpc44hd2ZiQWjMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkK5OEDPxE1? MX6yNVgyOjRzNB?=
HEK293 MWLGeY5kfGmxbjDBd5NigQ>? NFLWXooyKGh? Mmj4SG1UVw>? MonmTY5pcWKrdHnvckBw\iCLUjDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi56OEeg{txO NVjlV2M4OjF6MUK0NVQ>
Jurkat MWDGeY5kfGmxbjDBd5NigQ>? MlS2NUBp MVjEUXNQ MUTJcohq[mm2aX;uJI9nKEyFSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOi55NEGg{txO NVz4[JBiOjF6MUK0NVQ>
KARPAS299 NV;KS|ZwU2mwYYPlJGF{e2G7 MnPjNUBp NV7WW2VDTE2VTx?= MUPJcohq[mm2aX;uJI9nKEGOSzDhd5Nme3OnZDDhd{Boem:5dHig[oFkfG:{LXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> MXmyNVgyOjRzNB?=
PAE MnztSpVv[3Srb36gRZN{[Xl? MmTINUBp M2nZOWROW09? NETZPG9KdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= M4P2cFIyQDF{NEG0
BAF3 M3GwZmZ2dmO2aX;uJGF{e2G7 NXHVVVRpOi1|IHS= MkfmSG1UVw>? NELpXoRKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO NF;BRo4zOzd2MkK1Ni=>
KARPAS299 NFjSTFlEgXSxdH;4bYMhSXO|YYm= M{iyO|IuOyCm MnXWSG1UVw>? MmT5TWM2OD1yLkC2OFIh|ryP NFHIXWYzOzd2MkK1Ni=>
EBC1 NV;ZTIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NkBp NH\Oe|BFVVOR MY\JR|UxRTBwMEKzJO69VQ>? M1;iWFI{QTl|M{K4
HCT116 NH7DfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPpb3VZPzJiaB?= MlPVSG1UVw>? NWDSS5hzUUN3ME2xOE45OiEQvF2= M1\oeFI{QTl|M{K4
MCF7 NELKbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;r[GZIPzJiaB?= NXrVTIdsTE2VTx?= MW\JR|UxRTlwNUig{txO M4\ENVI{QTl|M{K4
MDA-MB-231 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTqbXc4OiCq MV;EUXNQ NXjzV5o6UUN3ME2xNE45KM7:TR?= NE\pNmwzOzl7M{OyPC=>
MKN45 M17Rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\YdlczKGh? NGH0T5BFVVOR NV3HVJJbUUN3ME2wMlAyOyEQvF2= MVWyN|k6OzN{OB?=
NCI-H441 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe4ZmxqPzJiaB?= NGToVo1FVVOR MmLFTWM2OD1zNz6yOUDPxE1? Mo\wNlM6QTN|Mki=
NCI-H661 NHrCcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\wO|IhcA>? MnrkSG1UVw>? NWH2cpQzUUN3ME2xNU41PyEQvF2= NEDkSIgzOzl7M{OyPC=>
SK-MEL-28 NVzyOo8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO3NkBp MnnDSG1UVw>? NEPw[FVKSzVyPUGwMlk4KM7:TR?= NYPRd494OjN7OUOzNlg>
SKOV3 NIjwO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4m5OlczKGh? MkLjSG1UVw>? NE\ibHpKSzVyPUGyMlg2KM7:TR?= NVLTT4p3OjN7OUOzNlg>
SNU5 M3jYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLpO|IhcA>? Mn\aSG1UVw>? NF\VcVNKSzVyPUCuNFE3KM7:TR?= MljWNlM6QTN|Mki=
NCI-H2228 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPlO|IhcA>? MV\EUXNQ MYHJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiC5aYToJGlEPTBib3[gNE4yOThizszN NXPQNnlMOjR2M{K5NFk>
NCI-H3122 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7rc2FXPzJiaB?= NGT6OJVFVVOR Moi4TY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTB6IN88US=> NWfFdW0yOjR2M{K5NFk>
NCI-H3122 M4rqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T2SlczKGh? M{nocGROW09? NILINZpKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjDpckBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiaHHyZo9zcW6pIFHMT{BIOTJ4OVGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjZ{MzFOwG0> M1;2U|I1PDN{OUC5
NCI-H3122 NHjsXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXi3NkBp MkP3SG1UVw>? MWPJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= MlzLNlQ1OzJ7MEm=
NIH-3T3 M4XlU2tqdmG|ZTDBd5NigQ>? MUWxJIg> M2TlcWROW09? M{DqU2lvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKEWPTESt[pV{\WRiQVzLJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCyaH;zdIhwenmuYYTl[EBCVEtibHX2[Ywhf2m2aDDJR|UxKG:oIECuNFgh|ryP MViyOFQ{OjlyOR?=
NIH-3T3 NGHGfYxMcW6jc3WgRZN{[Xl? MoTlNUBp Mm\zSG1UVw>? NF3N[o5KdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGcyOjZ7QTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLk[wOUDPxE1? MWKyOFQ{OjlyOR?=
NIH-3T3 NFjnVYRMcW6jc3WgRZN{[Xl? NXXuS3dHOSCq M3r5OGROW09? MnP5TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDTNVIxPllibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC54Mk[g{txO NHnkTVgzPDR|MkmwPS=>
NIH-3T3 NUTFT5UyU2mwYYPlJGF{e2G7 M1Hre|EhcA>? NXXkXnF{TE2VTx?= NFL4[WdKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1? M3TFdlI1PDN{OUC5
NIH-3T3 NVrpbnBMU2mwYYPlJGF{e2G7 M{Lj[|EhcA>? NFLmTGJFVVOR NXuwdmNiUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh|ryP NGfnR4ozPDR|MkmwPS=>
BAF3 M2TTOmZ2dmO2aX;uJGF{e2G7 MljCO|IhcA>? NY\RXnV4TE2VTx?= M2i0d2lvcGmkaYTpc44hd2ZiTmDNM2FNUyC2cnHud4Zm[3SnZDDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjB3MTFOwG0> Mlr0NlQ1Pjh4M{K=
BAF3 MVjDfZRwfG:6aXOgRZN{[Xl? NFvFfZQ4OiCq NEnZfI9FVVOR M3jKemlEPTB;MD65PEDPxE1? MWiyOFQ3QDZ|Mh?=
NIH-3T3 M2L4WWtqdmG|ZTDBd5NigQ>? Mn\pNUBp NIj6c4dKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGYyOTd2TDDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkG2OUDPxE1? MUiyOFgyQTFzNh?=
NIH-3T3 NFnYWFBMcW6jc3WgRZN{[Xl? MoPuNUBp NWnGcGZIUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD60O|gh|ryP NFrl[XYzPDhzOUGxOi=>
NIH-3T3 MlqwT4lv[XOnIFHzd4F6 MWexJIg> MULJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAyNjF2ODFOwG0> Mmm4NlQ5OTlzMU[=
NIH-3T3 NYj0VmNKU2mwYYPlJGF{e2G7 M2j4RlEhcA>? NUXCRmZqUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKHerdHigTWM2OCCxZjCzMlA{QSEQvF2= MlL5NlQ5OTlzMU[=
KARPAS299 MXLLbY5ie2ViQYPzZZk> NFj0eJk6OCCvaX6= Ml6zSG1UVw>? MlSzTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO Mo\lNlQ6ODB5NUC=
MKN 45 NXXIcVRRU2mwYYPlJGF{e2G7 NWf4RZg3OSCq M2nqTWROW09? M4jPdGlvcGmkaYTpc44hd2ZiYz3N[ZQheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>? MYKyOFkxODd3MB?=
A549 MkjNR5l1d3SxeHnjJGF{e2G7 NV\HdphbPDhiaB?= MVnEUXNQ MnPOTWM2OCCxZjC0MlA5PCEQvF2= NHTE[HAzPDlyMEizNC=>
NCI-H1975 MknER5l1d3SxeHnjJGF{e2G7 M3TO[FQ5KGh? NVP3fmVPTE2VTx?= NHTtZ|RKSzVyIH;mJFcvPTVzIN88US=> Ml:zNlQ6ODB6M{C=
NCI-H1993 NVK2R49uS3m2b4TvfIlkKEG|c3H5 NVO2T|dIPDhiaB?= MXTEUXNQ NGC4NGhKSzVyIH;mJFAvODZzIN88US=> MmnKNlQ6ODB6M{C=
NCI-H1993 M3[0fmFxd3Sxc3nzJGF{e2G7 M3ziOlEh|ryP NUXaNGVWOjRiaB?= M4ezTmROW09? NWHlb2E3\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> NF7sTG0zPDlyMEizNC=>
NIH-3T3 M1rTSWN6fG:2b4jpZ{BCe3OjeR?= NFrJb4Y1QCCq M1vXNGROW09? NITCS4JKSzVyIH;mJFAvOzZ2IN88US=> NVPoOotuOjR7MEC4N|A>
EBC1 NEjIclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe2R2M4OiCq M1HMSmROW09? NYrBbWdZUUN3MDDv[kAxNjByNkmg{txO MWmyOFkxODh|MR?=
KARPAS299 M3z4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnwO|IhcA>? M4nhT2ROW09? NXrC[|Y5UUN3MDDv[kAxNjJizszN M{\KUVI1QTByOEOx
NB1 NGrCOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTlzLkm4JI5O NYTudXpMW0GQR1XS
NCI-SNU-5 M2SyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILIdXVKSzVyPUGwOU44PSCwTR?= NH3SRm5USU6JRWK=
SR NIrKN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H3NmlEPTB;MUK2MlMyKG6P NWnHbm86W0GQR1XS
SF539 NX;5fWs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3jXGFKSzVyPUKwOE4zPCCwTR?= NUWyc4ptW0GQR1XS
SU-DHL-1 NUjGfYNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTN|Nj64NkBvVQ>? MXvTRW5ITVJ?
SCC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TIcGlEPTB;M{W2Mlc3KG6P NG[3R5JUSU6JRWK=
DEL NVvwSIlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN4OT65JI5O NW\6cFVMW0GQR1XS
CTV-1 NUPPRYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\N[WlEPTB;NUm2MlQ5KG6P MVjTRW5ITVJ?
EM-2 NEDZTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqyPHVKSzVyPU[wNU4{PCCwTR?= M2HiV3NCVkeHUh?=
MHH-CALL-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjQTWM2OD14OEKuOVchdk1? MlKwV2FPT0WU
KM12 M4D6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[z[VBKSzVyPUewOk46KG6P MV;TRW5ITVJ?
KINGS-1 NUfWTmhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3kTWM2OD15NEmuO|Uhdk1? MXHTRW5ITVJ?
MEG-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XobGlEPTB;OEW3MlY3KG6P MW\TRW5ITVJ?
BV-173 NXX6c5BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmToTWM2OD1zLkC1PVk4KM7:TR?= M3nwXXNCVkeHUh?=
LAMA-84 NF2w[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET5SGpKSzVyPUGuN|gzQDJizszN MYDTRW5ITVJ?
KARPAS-299 M1;LWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HJ[WlEPTB;MT60NFg3OSEQvF2= M2TvdXNCVkeHUh?=
K-562 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITPfoNKSzVyPUGuO|IzPjlizszN M4XsPXNCVkeHUh?=
SK-LMS-1 NVvFPXp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL6b2dpUUN3ME2xMlc3QDZ5IN88US=> MXLTRW5ITVJ?
MOLT-16 M4n6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[5Z4NmUUN3ME2xMlk2PTd3IN88US=> Mn;FV2FPT0WU
CMK NIjrTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwOU[xOVkh|ryP NFnuTplUSU6JRWK=
ST486 M33SSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwNEOwO|Mh|ryP MliwV2FPT0WU
CI-1 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfUXoloUUN3ME2yMlQ6PjV7IN88US=> MWHTRW5ITVJ?
KP-N-RT-BM-1 NWHlPHpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\0WWlEPTB;Mj63NFEzOiEQvF2= M33oR3NCVkeHUh?=
ALL-PO MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTNwMUiyNFch|ryP NXzmPZUxW0GQR1XS
KS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\ITWM2OD1|LkKxNlI2KM7:TR?= NV\nOVB[W0GQR1XS
Becker M4fZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHWU5B2UUN3ME20MlI{QTNizszN MkXCV2FPT0WU
GDM-1 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDmTWM2OD12LkK0OlE4KM7:TR?= M4\6XXNCVkeHUh?=
BC-1 M3\lfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\YTWM2OD12LkS5Nlc4KM7:TR?= MnjNV2FPT0WU
NB14 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonjTWM2OD12LkizOVI1KM7:TR?= MXTTRW5ITVJ?
NOS-1 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nIUGlEPTB;NT6zN|g4PCEQvF2= M2jRTnNCVkeHUh?=
MZ1-PC NWXXclZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\yfFNOUUN3ME21MlgzOTVzIN88US=> NFnsV41USU6JRWK=
A498 MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTUSml1UUN3ME22MlA5PDd|IN88US=> NFvXZYVUSU6JRWK=
EW-16 NH;lSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDaTWM2OD14LkO3O|c{KM7:TR?= M{PIbnNCVkeHUh?=
NALM-6 NEXqTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrUXo0xUUN3ME22MlY5Ozh5IN88US=> M{L0cHNCVkeHUh?=
EB-3 NWTaSmpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW4ToJ6UUN3ME23MlA4OjN|IN88US=> MlzhV2FPT0WU
697 NFjjPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m4W2lEPTB;OT6yOFMzQSEQvF2= NIPSVVdUSU6JRWK=
Ramos-2G6-4C10 NEPWZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGniZXNKSzVyPUmuOVk5PDJizszN M4S3fXNCVkeHUh?=
KNS-81-FD NF75eYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\0OG1[UUN3ME25MlY6PjV|IN88US=> NG\POpFUSU6JRWK=
HUTU-80 NETHZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjDdoRKUUN3ME25Mlc1PjR{IN88US=> M1T4b3NCVkeHUh?=
LS-411N NH7BW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHxc3lKSzVyPUGwMlA2PjdizszN MnnmV2FPT0WU
RPMI-8402 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ezUmlEPTB;MUCuNVE3KM7:TR?= MXzTRW5ITVJ?
KU812 NXjTeYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfaVmlKSzVyPUGwMlI6QTFizszN MmX2V2FPT0WU
EW-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\INnVKSzVyPUGwMlQ1OjVizszN NG[4V5pUSU6JRWK=
HC-1 NVTXWGFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFyLkS4OFQh|ryP M2LFU3NCVkeHUh?=
NB69 NYfLXlhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXTTWM2OD1zMD61NFQ{KM7:TR?= NIjaeoVUSU6JRWK=
MFH-ino M3zTPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG1U4tPUUN3ME2xNE45OzB|IN88US=> NWLBNo1GW0GQR1XS
CCRF-CEM MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\kO2lKSzVyPUGxMlU6PyEQvF2= MmfSV2FPT0WU
SK-N-DZ NUTRTXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF{LkC0N|Yh|ryP NH31VnVUSU6JRWK=
NCI-H720 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojyTWM2OD1zMj6xO|A2KM7:TR?= MX3TRW5ITVJ?
HCC1187 MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTmTWM2OD1zMj6yNFQyKM7:TR?= M2THWnNCVkeHUh?=
IST-SL2 M2XGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF{LkS4O|Ih|ryP MXnTRW5ITVJ?
KE-37 NHrSd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml21TWM2OD1zMj63PVY3KM7:TR?= NGroW3pUSU6JRWK=
HCC1599 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:3[|NpUUN3ME2xNk46ODZ7IN88US=> NFL3NJlUSU6JRWK=
A4-Fuk M3f0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHsT|F1UUN3ME2xNk46PTh4IN88US=> NE\y[m5USU6JRWK=
NKM-1 NF3wdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVThVZJkUUN3ME2xN{4zQTJ3IN88US=> NYDrcYZDW0GQR1XS
BE-13 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljNTWM2OD1zMz63PVg6KM7:TR?= Mki1V2FPT0WU
MV-4-11 NUXyS3hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;nZoNOUUN3ME2xOE4xOzJ2IN88US=> M1niXXNCVkeHUh?=
OPM-2 M2C2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm1O2ZKSzVyPUG0MlQxQDVizszN M2DPSnNCVkeHUh?=
KARPAS-422 NUDjVotXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF2LkWxNlYh|ryP M136V3NCVkeHUh?=
RPMI-8226 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF2Lki5NVUh|ryP NGrZe29USU6JRWK=
KARPAS-45 M{TjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLSXZVKSzVyPUG1Mlc4OTZizszN MVnTRW5ITVJ?
SK-PN-DW M2HySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TGUWlEPTB;MUWuPFY{OSEQvF2= NEO5UXhUSU6JRWK=
LC-2 NWPNZ2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jpPWlEPTB;MU[uNVUxPiEQvF2= MXLTRW5ITVJ?
NCI-H1648 NVLGTmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PnVWlEPTB;MU[uNlU1KM7:TR?= MmrmV2FPT0WU
RL95-2 NHq4NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF4LkO5O|gh|ryP NH\QSoxUSU6JRWK=
KNS-42 NIHPTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj0TWM2OD1zNj63Nlc1KM7:TR?= NF\qT|RUSU6JRWK=
RPMI-6666 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF4LkmyNVEh|ryP NXTFbmhNW0GQR1XS
SIG-M5 M3rVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HY[mlEPTB;MUeuNVkxOyEQvF2= MW\TRW5ITVJ?
VA-ES-BJ NGTNSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEC4bZJKSzVyPUG3Mlc1PTFizszN MoDqV2FPT0WU
MONO-MAC-6 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF5LkmzNVIh|ryP MmrjV2FPT0WU
LAN-6 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTPUpNKSzVyPUG4Mlc2PTdizszN MWPTRW5ITVJ?
A388 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom0TWM2OD1zOT6zNFU6KM7:TR?= M3jkU3NCVkeHUh?=
SK-NEP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJyLkKxN|Ih|ryP M3TxbXNCVkeHUh?=
TE-10 NYfBW4lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT4b2tMUUN3ME2yNE42OjJzIN88US=> MlvpV2FPT0WU
HL-60 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO1cnFxUUN3ME2yNE46ODl7IN88US=> M2\SVnNCVkeHUh?=
MC116 NH\X[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;wXHdKSzVyPUKxMlczOjFizszN NH\ZcJdUSU6JRWK=
SW962 NYTXdW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLMTWM2OD1{MT63PVE2KM7:TR?= M1Kxb3NCVkeHUh?=
NOMO-1 NEfuSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ{Lk[1OlQh|ryP M3\4XHNCVkeHUh?=
CTB-1 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXu[odKSzVyPUKyMlg3PzFizszN NW\sbnY5W0GQR1XS
MRK-nu-1 M1PhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jlfGlEPTB;MkKuPVA4PCEQvF2= M3La[nNCVkeHUh?=
GR-ST NXq1UZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS2TWM2OD1{Mz63OkDPxE1? M2rpdHNCVkeHUh?=
HH M4LRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSxUHM2UUN3ME2yOE4xODNizszN NGTPeoxUSU6JRWK=
NCI-H1963 NIjFXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr2RlJQUUN3ME2yOE4xPzh{IN88US=> MlS0V2FPT0WU
QIMR-WIL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ2Lki3O|Ih|ryP NH\JbnRUSU6JRWK=
CGTH-W-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonPTWM2OD1{NT6wO|I{KM7:TR?= NIjmVVVUSU6JRWK=
LP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fUZWlEPTB;MkWuOlU2OSEQvF2= NIXPNWlUSU6JRWK=
NCI-H748 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX6TWM2OD1{Nj61NVM4KM7:TR?= NGOzSWNUSU6JRWK=
PF-382 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ5LkKyNlMh|ryP NGrUfo9USU6JRWK=
ATN-1 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlSwTWM2OD1{Nz6zO|MzKM7:TR?= NGnPdXpUSU6JRWK=
L-540 NXriNGM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ5Lk[0OVkh|ryP NFuzOpZUSU6JRWK=
LXF-289 NUHPPW9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ5Lke1NVkh|ryP MV\TRW5ITVJ?
LS-513 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULNTINtUUN3ME2yPE4yQDB5IN88US=> M1Wx[HNCVkeHUh?=
NCI-H1581 M1PSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNyLkO5O|Yh|ryP MYLTRW5ITVJ?
ES6 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvkWJNKSzVyPUOwMlY5QTlizszN NHzk[FRUSU6JRWK=
SW982 NV3lVI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LBcmlEPTB;M{CuPFU3PiEQvF2= NED0OYtUSU6JRWK=
DOHH-2 NHHodVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNzLkW4PVMh|ryP MXjTRW5ITVJ?
DB NHXGPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL6dHJRUUN3ME2zN{46PDNzIN88US=> MYTTRW5ITVJ?
MPP-89 NHq0VIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\HeGlEPTB;M{SuNVc2PiEQvF2= NIPJSGdUSU6JRWK=
LB831-BLC M4OySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN2LkWxPFQh|ryP MkfrV2FPT0WU
NB5 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN2Lki1N|Uh|ryP MlrvV2FPT0WU
GB-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN3LkC0Olkh|ryP MlTzV2FPT0WU
TE-15 NF7ldotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN3LkKyN|gh|ryP MnrZV2FPT0WU
LC4-1 M4jhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nYbmlEPTB;M{WuN|g1PyEQvF2= NF7Fdo5USU6JRWK=
NCI-H747 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN4LkGzOlkh|ryP MYnTRW5ITVJ?
NTERA-S-cl-D1 M3vveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN6LkezOFch|ryP MYfTRW5ITVJ?
SK-MM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\LTWM2OD12MD6xNVQ3KM7:TR?= MX3TRW5ITVJ?
TGW M1rZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml70TWM2OD12MT6wOVY{KM7:TR?= NILObXNUSU6JRWK=
ONS-76 M37KU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\oTWlEPTB;NEKuOFg5OyEQvF2= MXXTRW5ITVJ?
CPC-N NGDzW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP3fZZKSzVyPUSyMlk6PzFizszN MYLTRW5ITVJ?
ES4 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;mXGlEPTB;NESuOFE2OyEQvF2= Mk\pV2FPT0WU
Daudi MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2y[FJyUUN3ME20OU4xQDJ5IN88US=> MnnlV2FPT0WU
MOLT-4 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX30OGw3UUN3ME20OU4xQDV|IN88US=> NVXkc5NwW0GQR1XS
HT-144 M37K[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR4LkeyOkDPxE1? NUDXUod4W0GQR1XS
SW872 NUWxSYZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[2[mN[UUN3ME20PE4yQTN|IN88US=> NHv5dJlUSU6JRWK=
D-283MED MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\4XpBZUUN3ME20PE4{PTR{IN88US=> MnzuV2FPT0WU
NCI-H2126 NYnFZ2dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTR6Lki0O|Yh|ryP M1rhN3NCVkeHUh?=
NCI-SNU-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzE[2RKSzVyPUS5MlIyPDNizszN MX\TRW5ITVJ?
CESS NXeyc3hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDcXpKSzVyPUS5MlUxQDhizszN MWHTRW5ITVJ?
A101D NFrLU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[xPWlEPTB;NEmuPVc{PiEQvF2= MVTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:

[1]

+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:

[1]

+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method:

    Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231
  • Formulation: --
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+dd H2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT01979536 Recruiting Anaplastic Large Cell Lymphoma ALK-Positive|Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma|CD30-Positive Neoplastic Cells Present National Cancer Institute (NCI) November 8 2013 Phase 2
NCT02040870 Completed Non-Small Cell Lung Cancer Novartis Pharmaceuticals|Novartis March 7 2014 Phase 1|Phase 2
NCT01531361 Active not recruiting Advanced Malignant Neoplasm|BRAF Gene Mutation|Metastatic Malignant Neoplasm|Recurrent Malignant Neoplasm|Refractory Malignant Neoplasm M.D. Anderson Cancer Center|National Cancer Institute (NCI) February 6 2012 Phase 1
NCT02761057 Recruiting Stage III Renal Cell Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma National Cancer Institute (NCI) April 5 2016 Phase 2
NCT02094573 Active not recruiting Carcinoma Non-Small-Cell Lung Ariad Pharmaceuticals June 4 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • Answer:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID